Languages
Pages
Legal
Explore all categories to find your favorite topic
8/8/2019 Code of Conduct Novartis 1/12Issued by NovartisInternational AGApproved by the NovartisBoard of Directorson August 26, 1999Novartis Code of ConductRevised June 20018/8/2019…
The Novartis Vaccines and Diagnostics division is a leader in providing products to fight more than 20 vaccine-preventable viral and bacterial diseases. 200 users across…
8/11/2019 Ipr-group5 Novartis (1) 1/18 NOVARTIS AGINTELLECTUAL PROPERTY RIGHTSPresented By :Vidit Garg 221164Himalaya Tarani 221173Jai Chowdhary 221176Akshay Maken 221177Presented…
8/13/2019 Work Life Balance-Novartis 1/86TABLE OF CONTENTSCHAPTER NO TOPICS PAGE NO1INTRODUCTION 41.1 DEFINITION 51.3 COMPANY PROFILE 151.4 OBJECTIVES OF THE STUDY 191.5…
Annual Report 2015 BRINGING HEALTHCARE HOME Switzerland’s well-developed network of home healthcare workers is helping cope with an aging population. p STORY STARTS ON…
1. Industrial Training Overview on Novartis Bangladesh Limited (Tongi Plant) PreparedBy B.Pharm Professional Year-IV 2015 Exam 2. Introduction Company Profile : Name : Novartis…
Q2 2019 ResultsJuly 18, 2019 Disclaimer Novartis Q2 2019 Results | July 18, 2019 | Novartis Investor Presentation 2 This presentation contains forward-looking statements
1.Biosimilars: Principles of their Development and Evaluation Dr. Karin Heidenreich / Global Public Policy R&D Novartis International AG, Switzerland Workshop on Biotherapeutics…
Novartis Annual Report 2018Table of contents Introduction and use of certain terms .................................................................................................................................................................4
Meet Novartis ManagementOverview Disclaimer This presentation contains forward-looking statements within the meaning of the United States Private Securities Litigation Reform
Mayzent® -FDA approvalDanny Bar Zohar | Neuroscience Development Head March 27, 2019 Mayzent® - FDA approval This presentation contains forward-looking statements
Iptacopan UpdateNovartis Investor Relations This presentation contains forward-looking statements within the meaning of the United States Private Securities Litigation Reform
Microsoft PowerPoint - Turkey-Qualification_Validation.pptAndreas Brutsche Novartis Switzerland GMP Conference, 11.06.04, Istanbul Pharmaceutical Industry - Challenges and
Novartis Code of ConductCode of Conduct • Patients: Patient benefit and safety is at the heart of everything we do • Associates: We treat our associates fairly
Novartis Basic registration templateStudy CBYM338E2202E1 / NCT02468674 A 24 week off drug extension, parallel group, study assessing durability of effect on skeletal muscle
T2001-18Rx only Prescribing Information WARNING Only physicians experienced in management of systemic immunosuppressive therapy for the indicated disease should prescribe
Q4 2020 ResultsJanuary 26, 2021 Updated from January 26 to address clerical error on slide 126 and 127 Novartis Investor Relations Disclaimer This presentation contains forward-looking
A GLOBAL HEALTHCARE COMPANY by PIYUSH TRIPATHI [email protected] 1 Swiss MN Pharmaceutical Company Created in 1996 through a merger of Ciba-Geigy & Sandoz…
7/31/2019 Novartis Osteoporosis Slide Kit 1/42OsteoporosisandCurrent trends in themanagement of osteoporosis7/31/2019 Novartis Osteoporosis Slide Kit 2/42OsteoporosisA definitionA…